

Quzyttir™

Cetirizine HCl Injection

10mg/mL

INDICATIONS AND USAGE¹

Quzyttir® is a histamine-1 (H₁) receptor antagonist indicated for the treatment of acute urticaria in adults and children 6 months of age and older

Limitations of Use:

Not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function

DOSAGE AND ADMINISTRATION¹

For intravenous administration only

Recommended dosages:

- Adults and adolescents ≥ 12 years: 10 mg
- Children 6 to 11 years: 5 mg or 10 mg
- Children 6 months to 5 years: 2.5 mg

Recommended dosage regimen is once every 24 hours as needed for acute urticaria

Please see Important Safety Information on reverse side.



NDC 70720-100-25:

Carton containing 25 single-use vials (10 mg/mL cetirizine hydrochloride)

Authorized Specialty Distributors

Name	Customer Service	Order Times
Besse Medical	800-543-2111	Monday-Thursday 8:30 AM-7 PM ET, Friday 8:30 AM-5 PM ET
Cardinal Specialty	Oncology: 877-453-3972 Other Specialties: 866-300-3838	Monday-Friday 8 AM-7 PM ET
McKesson Plasma and Biologics	877-625-2566	Monday-Friday 9 AM-7:30 PM ET
McKesson Specialty	Oncology: 800-482-6700 Other Specialties: 855-477-9800	Monday-Friday 8 AM-8 PM ET
Metro Medical	800-768-2002	Monday-Friday 8 AM-8 PM ET
Oncology Supply	800-633-7555	Monday-Friday 9 AM-8 PM ET

1. QUZYTIR (cetirizine hydrochloride injection) [package insert]. Lake Forest, IL: TerSera Therapeutics LLC; 2019.

Indication and Important Safety Information
QUZYTIR™ (cetirizine hydrochloride injection), for intravenous use

INDICATIONS AND USAGE

QUZYTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.

Limitations of Use: QUZYTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

IMPORTANT SAFETY INFORMATION

Contraindications: Known hypersensitivity to QUZYTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Warnings and Precautions: The occurrence of somnolence/sedation has been reported in some patients. Advise patients to exercise due caution when driving, or when operating potentially dangerous machinery. Avoid concurrent use of QUZYTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur.

Adverse Reactions: The most common adverse reactions (incidence <1%) with QUZYTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis.

The most common adverse reactions (incidence $\geq 2\%$) with chronic dosing of oral cetirizine hydrochloride in adults are somnolence, fatigue, dry mouth, pharyngitis and dizziness. Adverse reactions observed in pediatric patients with chronic use of oral cetirizine hydrochloride are headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting.

For more information, please see the accompanying full Prescribing Information for QUZYTIR.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.